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Abstract
Aims/hypothesis Type 1 diabetes is preceded by a period of asymptomatic autoimmunity characterised by positivity for islet
autoantibodies. Therefore, T helper cell responses that induce B cell activation are likely to play a critical role in the disease
process. Here, we aimed to evaluate the role of a recently described subset, C-X-C motif chemokine receptor type 5-negative,
programmed cell death protein 1-positive (CXCR5−PD-1hi) peripheral T helper (Tph) cells, in human type 1 diabetes.
Methods The phenotype of blood CXCR5−PD-1hi CD4+ Tcells was analysed bymulticolour flow cytometry. The frequencies of
circulating CXCR5−PD-1hi T cells were analysed in a cohort of 44 children with newly diagnosed type 1 diabetes, 40
autoantibody-positive (AAb+) at-risk children and 84 autoantibody-negative healthy control children, and the findings were
replicated in a separate cohort of 15 children with newly diagnosed type 1 diabetes and 15 healthy control children.
Results Circulating CXCR5−PD-1hi Tph cells share several features associated with B cell helper function with circulating
CXCR5+PD-1hi follicular T helper (Tfh) cells. Moreover, the frequency of circulating Tph cells was increased in children with
newly diagnosed type 1 diabetes, especially in those who are positive for multiple autoantibodies. Importantly, circulating Tph
cells were also increased in autoantibody-positive at-risk children who later progressed to type 1 diabetes.
Conclusions/interpretation Our results demonstrate that circulating CXCR5−PD-1hi Tph cells are associated with progression to
clinical type 1 diabetes. Consequently, Tph cells could have potential both as a biomarker of disease progression and as a target
for immunotherapy in type 1 diabetes.
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Abbreviations
AAb+ Autoantibody-positive
CCR C-C motif chemokine receptor
CX3CR C-X3-C motif chemokine receptor
CXCL C-X-C motif chemokine ligand
CXCR C-X-C motif chemokine receptor
ICOS Inducible T cell costimulator
PD-1 Programmed cell death protein 1
PMA Phorbol myristic acid
TIGIT T cell immunoreceptor with Ig and ITIM domains
Tfh Follicular T helper
Tph Peripheral T helper
tSNE t-Distributed stochastic neighbour embedding
Introduction
Type 1 diabetes is a T cell-mediated autoimmune disease
characterised by beta cell destruction and dysfunction [1].
Autoantibodies produced by B cells are currently the best
available biomarker for predicting human type 1 diabetes.
Individuals positive for at least two islet autoantibodies have
around 50% risk of developing type 1 diabetes within the next
5 years [2]. Despite the predictive potential of autoantibodies,
it remains unclear whether autoreactive B cells have a direct
pathological effect in the pathogenesis of type 1 diabetes.
However, several studies have shown that B cells are abun-
dant in the pancreatic islets of some individuals with type 1
diabetes, especially in those who are diagnosed at a young age
and therefore likely have aggressive autoimmunity [3–5].
Moreover, one clinical trial has demonstrated a partial preser-
vation of C-peptide levels after B cell depletion by rituximab
[6].
Antibody production by B cells is strongly dependent on
the help provided by helper T cells, especially CXCR5+ fol-
licular T helper (Tfh) cells [7, 8]. We and others have demon-
strated that circulating Tfh cells appear to be increased in
individuals with type 1 diabetes [9–11]. Our study additional-
ly suggested that this increase occurs close to the clinical di-
agnosis of the disease and only in individuals positive for
multiple autoantibodies at diagnosis [11].
Recently, a novel population of CXCR5−PD-1hi CD4+ T
cells, coined peripheral T helper (Tph) cells, was shown to be
strongly expanded both in the synovium and in the peripheral
blood of individuals with seropositive rheumatoid arthritis
[12]. These CXCR5−PD-1hi Tph cells appear phenotypically
similar to CXCR5+PD-1hi Tfh cells since they express factors
associated with B cell help, including IL-21 and inducible T
cell costimulator (ICOS) and are capable of providing B cell
help in vitro. However, instead of expressing CXCR5 that
enables Tfh cells to home to lymphoid follicles, Tph cells
express higher levels of chemokine receptors, such as C-C
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motif chemokine receptor 2 (CCR2), C-X3-C motif chemo-
kine receptor 1 (CX3CR1) and CCR5, which direct migration
to inflamed sites. Consequently, they are thought to play an
important role in supporting B cell responses in inflamed tis-
sues, complementing in this way the role of Tfh cells in lym-
phoid organs [13].
In the current study, we used samples from a large follow-
up study of children to analyse whether, in addition to circu-
lating Tfh cells, CXCR5−PD-1hi Tph frequencies are altered
during the development of type 1 diabetes.
Methods
Study participants The study cohort has been described in
detail previously [11]. In brief, samples analysed in this study
were collected between October 2013 and January 2016. In
total, we analysed 44 children with newly diagnosed type 1
diabetes (within a week of diagnosis, age 9.0 ± 3.6 years), 40
autoantibody-positive (AAb+) children (age 9.3 ± 4.7 years)
and a control group of 84 autoantibody-negative healthy chil-
dren of similar age (age 9.4 ± 3.8 years). The AAb+ children
and healthy control children participated in the Finnish Type 1
Diabetes Prediction and Prevention (DIPP) follow-up study
and had HLA types associated with increased risk for T1D.
All the samples were paired (i.e. a blood sample from an age-
andHLA-matched healthy control child was drawn, processed
and analysed on the same day as the sample from an AAb+
child or child with type 1 diabetes). Of the AAb+ children, 15
were diagnosed with type 1 diabetes 7–37months (mean ± SD
23 ± 10 months) after sampling (progressors) and 25 had not
progressed to clinical disease (non-progressors) during the 3–
5 years after sampling. An independent cohort of 15 children
with newly diagnosed type 1 diabetes and 15 control children
of similar age who were not part of the original cohort were
recruited for the validation experiments. The study was ap-
proved by local ethics committees in the participating univer-
sity hospitals (decisions 1.12.1994 and 375/13.02.00/2016).
All children participating in the study and/or their legal guard-
ians provided written informed consent, as mandated by the
Declaration of Helsinki.
Flow cytometric analyses Immunostaining for surface and in-
tracellular markers was performed as previously described
[11] and the antibodies used are listed in ESM Table 1. In
some experiments, T cell subsets were first isolated by flow
cytometric sorting (FACSAria III, BD Biosciences, San Jose,
CA, USA) and stimulated for 5 h with 50 ng/ml phorbol
myristic acid (PMA; Sigma-Aldrich, St Louis, MO, USA),
1 μg/ml ionomycin (Sigma-Aldrich) and 3 μg/ml brefeldin
A (Ebioscience, San Diego, CA, USA). The samples were
acquired on FACSCanto II (BD Biosciences) or Cytoflex S
(Beckman Coulter, Indianapolis, IN, USA) flow cytometers
and the flow cytometry data was analysed using FlowJo soft-
ware v10 (BD Biosciences). Coded samples were used
throughout, and the flow cytometric analyses were performed
blinded to the clinical classification of the sample.
T cell and B cell co-cultures The co-culture approach has been
described in detail previously [11]. In brief, different T cell
subsets as well as naive (CD20+IgD+CD27−) or memory
(CD20+CD27+) B cells were flow-cytometrically sorted from
peripheral blood mononuclear cells of healthy donors, and T
cells and B cells were co-cultured together at a 1:10 ratio in the
presence of 1 μg/ml Staphylococcus enterotoxin B (SEB) and
5 μg/ml lipopolysaccharide (LPS; both from Sigma-Aldrich)
for 7 days before flow cytometric analyses (ESM Table 1 and
ESM Fig. 1).
Statistical analyses Statistical analyses were performed using
Prism software (GraphPad Software, San Diego, CA, USA).
When comparing differences between groups either Mann–
Whitney U test or Kruskal–Wallis test with Dunn’s multiple
comparison test was used. Wilcoxon test was used when
analysing paired samples. Relationships between different re-
sults were examined using Spearman correlation coefficient.
p < 0.05 was considered to indicate statistical significance.
Results
Circulating CXCR5−PD-1hi Tph cells express factors associated
with B cell helper function and resemble circulating
CXCR5+PD-1hi Tfh cells Based on the expression of CXCR5
and programmed cell death protein 1 (PD-1), human periph-
eral blood memory CD4+ T cells can be subdivided into PD-
1−, PD-1int and PD-1hi subsets that are either CXCR5− or
CXCR5+ (Fig. 1a). The PD-1hi subsets are rare, typically com-
prising only 0.5–2% of total memory CD4+ T cells. First, we
analysed the expression of markers that are associated with B
cell helper function, differentiation status or homing capacity
on these memory CD4+ T cell subsets. In line with previously
published results [12], both the CXCR5−PD-1hi and
CXCR5+PD-1hi subsets expressed high levels of ICOS,
HLA-DR and T cell immunoreceptor with Ig and ITIM do-
mains (TIGIT) (Fig. 1b–d), with higher expression levels of
HLA-DR and lower expression of TIGIT observed in
CXCR5−PD-1hi compared with CXCR5+PD-1hi (Fig. 1c,d).
Moreover, these subsets differed in their expression of chemo-
kine receptors and markers of differentiation, with
CXCR5−PD-1hi cells expressing higher levels of CCR2,
CCR5 and CX3CR1 but lower levels of CCR7 and CD27 than
CXCR5+PD-1hi cells (Fig. 1e–i). Consequently, a larger frac-
tion of CXCR5−PD-1hi than CXCR5+PD-1hi cells reside with-
in the effector memory T cell compartment (ESM Fig. 1).
Both CXCR5−PD-1hi and CXCR5+PD-1hi subsets expressed
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high levels of Ki67 ex vivo, suggesting that they contain re-
cently activated cells proliferating in vivo (Fig. 1j). After
PMA and ionomycin stimulation, the frequencies of
CXCR5−PD-1hi and CXCR5+PD-1hi cells producing IL-21
and IL-2 were comparable, but clearly higher and lower, re-
spectively, compared with the PD-1− subsets (Fig. 1k,l). A
greater proportion of CXCR5−PD-1hi cells produced IFN-γ
compared with CXCR5+PD-1hi cells (Fig. 1m). Finally, we
directly compared the capacity of the different T cell subsets
to activate B cells in co-culture assays in vitro (ESM Fig. 1).
Interestingly, both CXCR5−PD-1hi and CXCR5+PD-1hi cells
were efficient in activating memory B cells into plasma cells,
with CXCR5−PD-1int cells also demonstrating this capacity
(Fig. 1n and ESM Fig. 1). In turn, the CXCR5+PD-1− and
CXCR5+PD-1int subsets were most efficient in activating na-
ive B cells into plasmablasts (ESM Fig. 1). Of note, all
memory T cell subsets were equally expanded during a
7 day co-culture with memory B cells, excluding the possibil-
ity that high PD-1 expression is associated with an exhausted
phenotype (ESM Fig. 1). Collectively, we demonstrate here
that circulating CXCR5−PD-1hi Tph cells appear to share sev-
eral characteristics with circulating CXCR5+PD-1hi Tfh cells,
with high expression of markers associated with B cell helper
capacity, such as ICOS, TIGIT and IL-21, and comparable
capacity to activate memory B cells in vitro.
Circulating CXCR5−PD-1hi Tph cells are increased in frequency
in children with newly diagnosed type 1 diabetes and in
autoantibody-positive children who later progressed to clin-
ical disease To analyse whether changes in circulating
CXCR5−PD-1hi Tph cell frequencies are altered in human
type 1 diabetes, we re-analysed data from our large published
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Fig. 1 CXCR5−PD-1hi Tph and CXCR5+PD-1hi Tfh CD4+ memory T
cell subsets share features associated with B cell helper function. (a) A
representative flow cytometric staining of peripheral blood memory T
cells (gated as CD3+CD4+CD45RA−) subdivided into CXCR5− (red)
and CXCR5+ (blue), and further into PD-1−, PD-1int and PD-1hi subsets.
(b–n) The expression of different surface markers (b–i) and the prolifer-
ation marker Ki67 (j), the production of cytokines after PMA and
ionomycin stimulation (k–m) and the capacity to induce memory B cell
differentiation to plasma cells in a co-culture of the different subsets (n).
The results are expressed as mean ± SEM geometric mean fluorescence
intensity (MFI) values or percentage positive from four to eight experi-
ments, each performed with cells from different healthy donors. For cy-
tokine production and B cell co-culture experiments, the T cell subsets
were flow-cytometrically sorted before the analyses. *p<0.05, **p<0.01
and ***p<0.001 compared with naive CD4+ T cells (grey bars), or
CXCR5–PD-1hi vs CXCR5+PD-1hi subsets where indicated; Kruskal–
Wallis test with Dunn’s post hoc test
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study evaluating the frequencies of CXCR5+ Tfh cells at dif-
ferent stages of type 1 diabetes progression [11]. Since the
gating of PD-1hi cells in different samples is not clearly de-
fined, to minimise analytical bias we only included paired
samples from the original study where samples from AAb+
children or children with newly diagnosed type 1 diabetes
were drawn, processed and analysed together with a paired
sample from an autoantibody-negative child of similar age
on the same day (Fig. 2a,b).
The frequency of CXCR5−PD-1hi Tph cells was increased
in both children with type 1 diabetes and in AAb+ children
(Fig. 2c). In line with our published results [11], the frequency
of CXCR5+PD-1hi Tfh cells was, however, only increased in
children with type 1 diabetes (Fig. 2d). These results were
confirmed by a strict pairwise analysis of the samples proc-
essed and analysed in parallel on the same day (ESM Fig. 2).
Of note, the frequencies of CXCR5−PD-1int and CXCR5+PD-
1int T cells did not differ between the study groups (ESM Fig.
2), excluding the possibility that the increase in PD-1hi Tph
and Tfh subsets is caused by a general increase in PD-1 ex-
pression in children with type 1 diabetes or AAb+ children.
Interestingly, the frequency of CXCR5−PD-1hi Tph cells was
only increased in children with type 1 diabetes who were
positive for two or more autoantibodies (Fig. 2e), a
phenomenon that was also observed in CXCR5+PD-1hi Tfh
cells (ESM Fig. 2 and [11]).
The frequency of CXCR5−PD-1hi Tph cells within memo-
ry CD4+ T cells did not clearly change with the age of the
children (Fig. 2f). In contrast, the frequency of CXCR5+PD-
1hi Tfh cells decreased with age (ESM Fig. 2 and [11]). Of
note, the frequencies of CXCR5−PD-1hi Tph and
CXCR5+PD-1hi Tfh cells correlated significantly (r = 0.57,
p < 0.0001; Fig. 2g).
Importantly, we have follow-up data on the development of
type 1 diabetes in the AAb+ children after the samples were
analysed. When we divided the group of AAb+ children into
progressors and non-progressors to type 1 diabetes, we were
interested to observe that the frequency of CXCR5−PD-1hi
Tph cells was only increased in the children that later
progressed to type 1 diabetes (Fig. 2h and ESM Fig. 2).
Other factors potentially influencing the risk of disease pro-
gression, such as age, HLA class II genotype and autoanti-
body status, were comparable between the two groups (ESM
Table 2).
In conclusion, we demonstrate that both CXCR5−PD-1hi
Tph and CXCR5+PD-1hi Tfh cells are increased in the blood
of children with newly diagnosed type 1 diabetes, especially
in children with multiple autoantibodies. However, only Tph
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Fig. 2 Higher frequency of circulating CXCR5−PD-1hi Tph cells in chil-
dren with newly diagnosed type 1 diabetes and in autoantibody-positive
at-risk children who progressed to clinical disease. (a, b) Representative
example of pairwise analyses of CXCR5−PD-1hi Tph and CXCR5+PD-
1hi Tfh cells (as a percentage of total memory CD4+ T cells) from a
healthy control child (a) and a child with type 1 diabetes (T1D, b). (c,
d) The frequencies of CXCR5−PD-1hi Tph (c) and CXCR5+PD-1hi Tfh
(d) cells in healthy control children, autoantibody-positive (AAb+) chil-
dren and children with newly diagnosed type 1 diabetes. (e) CXCR5−PD-
1hi Tph cell frequencies in children with newly diagnosed type 1 diabetes
stratified according to the number of biochemical autoantibodies (insulin
autoantibodies [IAA], GAD antibodies [GADA] and islet antigen 2 anti-
bodies [IA-2A]) at the time of sampling. (f, g) The frequency of
CXCR5−PD-1hi Tph cells within memory CD4+ T cells did not correlate
with age (f) but did correlate with the frequency of CXCR5+PD-1hi Tfh
cells (g). Correlation was calculated by pooling all samples analysed and
is expressed together with p values next to the individual plots. (h) The
frequencies of CXCR5−PD-1hi Tph cells in AAb+ children who did not
progress (NP) or progressed (P) to type 1 diabetes. Median values with
interquartile range are shown. *p<0.05, **p<0.01 and ***p<0.001;
Kruskal–Wallis test with Dunn’s post hoc test
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cells and not Tfh cells appear to be increased in AAb+ children
who later progressed to clinical disease.
TIGIT expression is elevated in CXCR5−PD-1hi Tph cells from
children with newly diagnosed type 1 diabetes To validate
our results, we performed an extended flow cytometric anal-
ysis on an independent cohort of 15 children with newly di-
agnosed type 1 diabetes and 15 children of similar age as a
healthy control group. For this analysis, we added additional
markers previously suggested to be differentially expressed by
Tph cells (TIGIT, ICOS, HLA-DR, CCR2 and CD27) [12] to
determine whether a certain combination of these phenotypic
markers would better define the CXCR5−PD-1hi cell popula-
tion expanded in children with type 1 diabetes. In line with
published data [12], two-dimensional visualisation of memory
CD4+ T cells by t-distributed stochastic neighbour embedding
(tSNE) clustered the main populations of CXCR5−PD-1hi and
CXCR5+PD-1hi cells in close proximity, suggesting a similar
multidimensional phenotype (Fig. 3a). Both the CXCR5−PD-
1hi and CXCR5+PD-1hi clusters appeared to contain cells ex-
pressing high levels of TIGIT. Importantly, the frequency of
cells within the CXCR5−PD-1hi cluster was higher in children
with type 1 diabetes than in healthy controls (Fig. 3b). We
confirmed this finding through manual gating, comparing
the expression levels of the different phenotypic markers on
CXCR5−PD-1hi cells (ESM Fig. 2). The only marker that was
differentially expressed by CXCR5−PD-1hi cells from chil-
dren with vs without type 1 diabetes was TIGIT (ESM Fig.
2). Consequently, an increased frequency of CXCR5−PD-
1hiTIGIT+ circulating Tph cells was observed in children with
type 1 diabetes (ESM Fig. 2). In conclusion, the extended
analysis of the validation cohort confirms that CXCR5−PD-
1hi Tph cells are increased in the blood of children with type 1
diabetes and suggests that TIGIT may be a useful auxiliary
marker to define circulating Tph cells.
Discussion
In the current study, we demonstrate that circulating
CXCR5−PD-1hi memory CD4+ T cells display a B cell helper
phenotype ex vivo and appear to be expanded in children with
newly diagnosed type 1 diabetes as well as in autoantibody-
positive children who later progressed to clinical disease.
Expansion of CXCR5−PD-1hi T cells both in the synovium
and peripheral blood was first described in individuals with
rheumatoid arthritis [12]. To our knowledge, our study is the
first to describe the expansion of these cells in peripheral
blood of individuals with type 1 diabetes. In the previous
study, CXCR5−PD-1hi T cells were coined peripheral T helper
(Tph) cells in order to differentiate them from the better-
established subset of CXCR5+PD-1hi follicular T helper
(Tfh) cells [12]. Due to the capacity of Tph cells to activate
B cells and recruit them to the tissues through the production
of the C-X-C motif chemokine ligand 13 (CXCL13), they are
hypothesised to play an important role in supporting B cell
responses and the formation of ectopic lymphoid structures in
tissues under inflammatory conditions, complementing in this
Expression
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Fig. 3 CXCR5−PD-1hiTIGIT+ Tcells are increased in children with new-
ly diagnosed type 1 diabetes. (a) tSNE plots of memory CD4+ T cells
(pre-gated on viable CD3+CD4+CD45RA− cells) from a combined batch
of 10 children with type 1 diabetes (T1D) and 10 healthy children as the
control group. Colour indicates surface expression levels of labelled
markers. The manually gated CXCR5−PD-1hi cluster (red arrows) also
expresses high levels of TIGIT and co-localises with the CXCR5+PD-1hi
cluster (blue arrows). (b) The frequency of memory CD4+ T cells within
the CXCR5−PD-1hi cluster in 10 children with type 1 diabetes compared
with 10 healthy children (control group) analysed in batch.Median values
with interquartile range are shown. *p<0.05; Mann–Whitney U test
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way the role of Tfh cells in lymphoid organs [13]. A
CXCR5−PD-1hi population highly similar to Tph cells has
also been identified within tumour-infiltrating lymphocytes
in individuals with breast cancer [14]. Importantly, a recent
paper employing HLA class II tetramers to directly character-
ise gluten-specific T cells in the blood and gut of individuals
with coeliac disease demonstrated that the pathogenic antigen-
specific T cells in coeliac disease also have a CXCR5−PD-1hi
phenotype with high expression levels of IL-21 and CXCL13
transcripts, highly reminiscent of Tph cells [15]. In the same
paper, CXCR5−PD-1hi T cells were also shown to be expand-
ed in the blood of individuals with systemic sclerosis and
systemic lupus erythematosus, further suggesting that the ex-
pansion of Tph cells in blood is a feature shared by several
autoimmune diseases [15].
Based on both our current and previously published data
[12], circulating CXCR5−PD-1hi Tph cells are clearly a pop-
ulation with heterogeneous marker expression. Understanding
this heterogeneity better and identifying additional markers to
more unambiguously define circulating Tph cells associated
with autoimmunity is a major research goal for the future. Our
initial analyses indicate that TIGIT, an immunomodulatory
receptor also expressed at high levels by CXCR5+PD1hi Tfh
cells in blood and tonsils (Fig. 1; [12, 16]), shows promise as a
candidate auxiliary marker for the identification of potentially
pathogenic Tph cells in individuals with type 1 diabetes. It is
also unclear whether circulating Tph cells, or Tfh cells, in
individuals with type 1 diabetes-associated autoimmunity
contain T cells recognising beta cell antigens or whether they
represent expansions of ‘bystander’ T cells. Although techni-
cally challenging, future studies employing HLA class II tet-
ramers may shed light on this question, as recently demon-
strated in coeliac disease [15].
The developmental relationship between Tfh cells and Tph
cells is currently unclear: does a subset of Tfh cells differen-
tiate into Tph cells during the germinal centre reaction or do
Tph cells derive from separate peripheral effector T cells that
acquire B cell helper function [13]? The strong correlation
between circulating Tph and Tfh cell frequencies observed
in our study would support the hypothesis for a common de-
velopmental pathway.
An obvious caveat of our study is that we could only ana-
lyse Tph cells in blood samples. The frequency of
CXCR5−PD-1hi T cells in peripheral blood is low, on average
around 1% of memory CD4+ T cells, and the increase in cir-
culating Tph cell frequencies in children with type 1 diabetes
and AAb+ children and healthy control children is modest at
best. It is important to note, however, that the frequencies of
circulating Tph cells in the peripheral blood of individuals
with rheumatoid arthritis are also similarly low, even though
they constitute on average more than 25% of all CD4+ T cells
in synovial fluid or synovial tissue [12]. Therefore, it is pos-
sible that also in type 1 diabetes Tph cells could constitute a
major subpopulation of CD4+ T cells at the level of inflamed
islets.
In addition to the well-characterised predictive potential of
autoantibodies in type 1 diabetes, several lines of evidence
support the importance of B cell autoimmunity also directly
at the level of inflamed islets. In the NODmousemodel, B cell
infiltration and the generation of ectopic lymphoid structures
are a general feature of autoimmune insulitis [17–20].
Moreover, CXCL13, a chemokine produced by Tph cells
[12, 14], appears to be expressed at high levels in the islets
[20, 21]. Finally, CXCR5−ICOS+ IL-21-producing Tcells that
bear high resemblance to Tph cells have been reported to
infiltrate the islets in NOD mice [22]. Although ectopic lym-
phoid structures are absent in human islets, a B cell infiltration
is observed also in inflamed human islets, especially in indi-
viduals that are very young at onset of type 1 diabetes and thus
likely have a more aggressive disease course [3–5]. An impor-
tant goal for future studies is to address whether CD4+ T cells
in inflamed human islets that harbour B cells display a phe-
notype characteristic of Tph cells.
In conclusion, we demonstrate here that CXCR5−PD-1hi
Tph cells are expanded in the circulation before and at the
diagnosis of type 1 diabetes. Together with previous reports
on Tfh cells [9–11], our current results provide further support
for a critical role for interactions between Tcells and B cells in
the pathogenesis of type 1 diabetes and provide a rationale that
targeting these interactions could be therapeutically effective.
Moreover, since circulating Tph cells appear to be more pre-
dominantly expanded than Tfh cells in autoantibody-positive
children, they also show potential for further evaluation as a
biomarker of disease progression and for monitoring the ef-
fects of immunotherapy.
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